Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Comp
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans.Halberd Corporation's patented drug, LDN+, a combination of low-dose Nalt...
United States Williama Hartman William Hartman Halberd Corporation Warrior Foundation Development Agreement
Source: pharmiweb.com